Page 9 - Naomi Eichenbaum News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Clover’s COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a Booster GlobeNewswire March 17, 2022 --100% efficacy maintained against severe COVID-19 and 95% efficacy against hospitalization at five months after second dose of SCB-2019 (CpG 1018/Alum)-- SHANGHAI, China, March 17, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd....

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

05.01.2022 - Clover expects to recruit hundreds of new hires in the area to support preclinical development, process development and pilot manufacturing for novel vaccines and treatments based on Trimer-Tag platform and beyondCHENGDU, China, Jan. 05, 2022 ...

Clover expects to recruit hundreds of new hires in the area to support preclinical development, process development and pilot manufacturing for novel...

Clover's Recombinant Protein-based and Adjuvanted COVID-19 Vaccine), a global pivotal Phase 2/3 clinical trial evaluating the efficacy, safety and immunogenicity of SCB-2019 (CpG 1018/Alum), Clover's COVID-19 vaccine candidate. SPECTRA is a double-blind, randomized, controlled study of SCB-2019 (CpG 1018/Alum) administered in a two-dose regimen, 21 days apart. Global enrollment surpassed 29,000 adult and elderly participants resulting in one of the most ethnically diverse COVID-19 clinical trials conducted to date, including over 45% of participants from Asia, 45% from Latin America and th...